[1]
|
Brunton, L.L. (2011) Goodman and Gilman’s the pathophysiologic basis of therapeutics. 12th Edition, The McGraw-Hill Companies, Inc., New York.
|
[2]
|
Johnson, J.A. and Liggett, S.B. (2011) Cardiovascular pharmacogenomics of adrenergic receptor signaling: Clinical implications and future directions. Clinical Pharmacology & Therapeutics, 89, 366-378.
doi:10.1038/clpt.2010.315
|
[3]
|
Shin, J. and Johnson, J.A. (2007) Pharmacogenetics of beta-blockers. Pharmacotherapy, 27, 874-887.
doi:10.1592/phco.27.6.874
|
[4]
|
Johnson, J.A., Zineh, I., Puckett, B.J., McGorray, S.P., Yarandi, H.N. and Pauly, D.F. (2003) Beta1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clinical Pharmacology & Therapeutics, 74, 44-52. doi:10.1016/S0009-9236(03)00068-7
|
[5]
|
Stakos, D.A. and Boudoulas, H. (2002) Pharmacogenetics and pharmacogenomics in cardiology. The Hellenic Journal of Cardiology, 43, 1-15.
|
[6]
|
Papatheodorou, A., Makrythanasis, P., Kaliakatsos, M., Dimakou, A., Orfanidou, D., Roussos, C., et al. (2010) Development of novel microarray methodology for the study of mutations in the SERPINA1 and ADRB2 genes—their association with obstructive pulmonary disease and disseminated bronchiectasis in Greek patients. Clinical Biochemistry, 43, 43-50.
doi:10.1016/j.clinbiochem.2009.08.026
|
[7]
|
Shin, J., Lobmeyer, M.T., Gong, Y., Zineh, I., Langaee, T.Y., Yarandi, H., et al. (2007) Relation of beta(2)-adrenoceptor haplotype to risk of death and heart transplantation in patients with heart failure. American Journal of Cardiology, 99, 250-255.
doi:10.1016/j.amjcard.2006.08.020
|
[8]
|
Boudoulas, H., Reynolds, J.C., Mazzaferri, E. and Wooley, C.F. (1983) Mitral valve prolapse syndrome: The effect of adrenergic stimulation. Journal of the American College of Cardiology, 2, 638-644.
doi:10.1016/S0735-1097(83)80303-9
|
[9]
|
Voora, D. and Ginsburg, G.S. (2012) Clinical application of cardiovascular pharmacogenetics. Journal of the American College of Cardiology, 60, 9-20.
doi:10.1016/j.jacc.2012.01.067
|
[10]
|
Salari, K., Watkins, H. and Ashley, E.A. (2012) Personalized medicine: Hope or hype? The European Heart Journal, 33, 1564-1570. doi:10.1093/eurheartj/ehs112
|
[11]
|
Diogenis Laertios, “Pythagoras,” Vitae Philosophoru VIII, 8.33.6-8.34.6.
|
[12]
|
Humma, L.M., Puckett, B.J., Richasdson, H.E., Terra, S.G., Andrisin, T.E., Lejeune, B.L., et al. (2001) Effects of beta1-adrenergic polymorphisms on resting hemodynamics in patients undergoing diagnostic testing for ischemia. American Journal of Cardiology, 88, 1034-1037.
doi:10.1016/S0002-9149(01)01986-5
|
[13]
|
Peng, Y., Xue, H., Luo, L., Yao, W. and Li, R. (2009) Polymorphisms of the adrenergic receptor gene are associated with essential hypertension in Chinese. Clinical Chemistry and Laboratory Medicine, 47, 1227-1231.
doi:10.1515/CCLM.2009.276
|
[14]
|
Kaye, D.M., Smirk, B., Williams, C., Jennings, G., Esler, M. and Holst, D. (2003) Beta-adrenoreceptor genotype influences the response to carvedilol in patients with congestive heart failure. Pharmacogenetics, 13, 379-382.
doi:10.1097/00008571-200307000-00002
|
[15]
|
Borjesson, M., Magnusson, Y., Hjalmarson, A. and Anderson, B. (2000) A novel polymorphism in the gene coding for the beta 1-adrenergic receptor is associated with survival in patients with heart failure. The European Heart Journal, 21, 1853-1858.
doi:10.1053/euhj.1999.1994
|
[16]
|
Biolo, A., Clausell, N., Santos, K.G., Salvaro, R., AshtonProlla, P., Borges, A., et al. (2008) Impact of beta1-adrenergic receptor polymorphisms on susceptibility to heart failure, arrhythmogenesis, prognosis, and response to betablocker therapy. American Journal of Cardiology, 102, 726-732. doi:10.1016/j.amjcard.2008.04.070
|
[17]
|
Rydén, L., Ariniego, R., Arnman, K., Herlitz, J., Hjalmarson, A., Holmberg, S., et al. (1983) A double-blind trial of metoprolol in acute myocardial infarction. Effects on ventricular tachyarrhythmias. The New England Journal of Medicine, 308, 614-618.
doi:10.1056/NEJM198303173081102
|
[18]
|
Roqué, F., Amuchastegui, L.M., Lopez Morillos, M.A., Mon, G.A., Girotti, A.L., Drajer, S., et al. (1987) Beneficial effects of timolol on infarct size and late ventricular tachycardia in patients with acute myocardial infarction. Circulation, 76, 610-617. doi:10.1161/01.CIR.76.3.610
|
[19]
|
Boudoulas, H. (1990) Therapeutic interventions which may improve survival in patients with coronary artery disease. Acta Cardiologica, 45, 477-487.
|
[20]
|
The MIAMI Trial Research Group (1985) Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. The European Heart Journal, 6, 199-226.
|
[21]
|
Hjalmarson, A., Elmfeldt, D., Herlitz, J., Holmberg, S., Málek, I., Nyberg, G., et al. (1981) Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial. Lancet, 2, 823-827.
doi:10.1016/S0140-6736(81)91101-6
|
[22]
|
Hjalmarson, A., Herlitz, J., Holmberg, S., Rydén, L., Swedberg, K., Vedin, A., et al. (1983) The Goteborg metoprolol trial. Effects on mortality and morbidity in acute myocardial infarction. Circulation, 67, I26-I32.
|
[23]
|
Hjalmarson, A. and Olsson, G. (1991) Myocardial infarction. Effects of beta-blockade. Circulation, 84, VI101-VI107.
|
[24]
|
Chen, Z.M., Pan, H.C., Chen, Y.P., Peto, R., Collins, R., Jiang, L.X., et al. (2005) COMMIT (ClOpidogrel and Me-toprolol in Myocardial Infarction Trial) collaborative group. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: Randomised placebo-controlled trial. Lancet, 366, 1622-1632.
doi:10.1016/S0140-6736(05)67661-1
|
[25]
|
Johnson, J.A. (2008) Ethnic differences in cardiovascular drug response: Potential contribution of pharmacogenetics. Circulation, 23, 1383-1393.
doi:10.1161/CIRCULATIONAHA.107.704023
|
[26]
|
Suonsyrja, T., Donner, K., Hannila-Handelberg, T., Fodstad, H., Kontula, K. and Hiltunen, T.P. (2010) Common genetic variation of beta1and beta2-adrenergic receptor and response to four classes of antihypertensive treatment. Pharmacogenetics and Genomics, 20, 342-345.
doi:10.1097/FPC.0b013e328338e1b8
|
[27]
|
Parvez, B., Chopra, N., Rowan, S., Vaglio, J.C., Muhammad, R., Roden, D.M., et al. (2012) A common 1-adrenergic receptor polymorphism predicts favorable response to rate-control therapy in atrial fibrillation. Journal of the American College of Cardiology, 59, 49-56.
doi:10.1016/j.jacc.2011.08.061
|
[28]
|
Cresci, S., Dorn II, G.W., Jones, P.G., Beitelshees, A.L., Li, A.Y., Lenzini, P.A., et al. (2012) Adrenergic-pathway gene influence beta-blocker-related outcomes after acute coronary syndrome in a race-specific manner. Journal of the American College of Cardiology, 60, 898-907.
doi:10.1016/j.jacc.2012.02.051
|
[29]
|
Puri, R., Liew, G.Y.H., Nicholls, S.J., Nelson, A.J., Leong, D.P., Carbone, A., et al. (2012) Coronary 2-adrenoreceptors mediate endothelium-dependent vasoreactivity in humans: Novel insights from an in vivo intravascular ultrasound study. The European Heart Journal, 33, 495-504. doi:10.1093/eurheartj/ehr359
|
[30]
|
Evans, W.E. and Relling, M.V. (1999) Pharmacogenetics: Translating functional genomics into rational therapeutics. Science, 286, 487-91. doi:10.1126/science.286.5439.487
|
[31]
|
Wachter, S.B. and Gilbert, E.M. (2012) Beta-adrenergic receptors, from their discovery and characterization through their manipulation to beneficial clinical application. Cardiology, 122, 104-112. doi:10.1159/000339271
|
[32]
|
Roden, D.M., Altman, R.B., Benowitz, N.L., et al. (2006) Pharmacogenomics: Challenges and opportunities. Annals of Internal Medicine, 145, 749-757.
doi:10.7326/0003-4819-145-10-200611210-00007
|